Akums Drugs and Pharma has partnered with Leiutis Pharma and Biophore India Pharma for research and development of a range of products for multiple therapies. This association is set to bring succour in therapy areas of CNS disorders, pain management and hormonal disorders, where there is a gap in meeting the needs of patients in an effective, safe and convenient manner, a statement from Akums has said.
The partnership leverages the strengths of each of the companies resulting in an innovation strategy creating a value proposition to doctors and patients in India, the statement noted.
The focus of the companies in this partnership is to synergise capabilities, leverage research and bring innovative products in specific therapeutic areas, within the next five years, both in India and other global markets and with the first few products expected to be commercialised in the next two years. The agreement was signed at the CPHI event and exhibition today in the presence of Professor (Dr) Y K Gupta, President, AIIMS, Bhopal and President, AIIMS Jammu, and Former Dean and HoD, Pharmacology, AIIMS, Delhi.
“……..Global companies are looking towards India for differentiated research and innovative therapies. I am excited to know that Leiutis, Biophore and Akums have collaborated to introduce such differentiated and speciality products. The entire process, from basic Research API development and product manufacturing is based in India. This is exactly what is exciting for India and expected from Indian entrepreneurs. The innovative products from this association will bring laurels to Indian pharma industry,” Gupta said in the statement.
This tripartite association will see Akums manufacture and commercialise the products created by Leiutis Pharma and API from Biophore, added the statement.
The products will be launched and marketed in India and the rest of the world, in line with our government’s vision to research in India, “Make-in-India, Market globally,” especially because of its potential to bring about useful therapies and bridge the gaps in the treatment of ailments and diseases across the world, concluded the statement.